In a compelling Instagram Live interview held last week, Aaron Blocker, IBD advocate and patient influencer, sat down with Nir Salomon, ChB, co-founder of Evinature and Director of Integrative Medicine at Sheba Medical Center, to discuss the groundbreaking CurQD® Protocol and its expanding role in the treatment of inflammatory bowel disease (IBD).
Science-Backed Innovation for IBD Patients
Salomon, who recently relocated to Boulder, Colorado to oversee Evinature’s operations in the U.S., shared his clinical and research journey that led to the development of CurQD®. Developed over 12 years at Sheba—one of the world’s leading IBD research centers—CurQD® combines a gut-directed, high-purity form of curcumin with a standardized form of an indigo plant extract. These two compounds are combined into a rigorously tested nutraceutical protocol, specifically formulated for IBD.
What sets CurQD® apart, Salomon explained, is that it underwent placebo-controlled clinical trials, a rarity in the supplement world. These studies demonstrated significant results, including over 80% clinical improvement within 8 weeks for patients with moderate-to-severe ulcerative colitis, many of whom had failed pharmaceutical treatments.
Addressing Gaps in IBD Treatment
According to Salomon, CurQD® addresses two major shortcomings in IBD care: the low therapeutic ceiling of conventional drugs and the gap in patient adherence and follow-up. Through a proprietary digital patient support program, Evinature offers tailored follow-ups, adjustments to the treatment protocol, and continuous communication with patients—something traditional healthcare often lacks.
Patients begin their CurQD® journey with an online clinical assessment (available at evinature.com/take-assessment), which personalizes the protocol based on disease severity, symptoms, and concurrent medications. From there, a sequence of color-coded protocols—Red, Orange, Yellow, Green, Blue Plus, and Blue—guides patients through remission and maintenance.
Medical Community Embraces CurQD®
Salomon also highlighted that over 40 U.S. medical centers have already integrated CurQD® into their IBD care strategies. Centers such as Mount Sinai, Vanderbilt University, and University of Chicago have independently studied CurQD® in real-world settings, confirming its potential as an effective adjunct therapy.
Aaron Blocker, who has personally used the CurQD® Protocol as part of his IBD management, emphasized the importance of clinical rigor and physician communication when choosing supplements. Salomon echoed this, pointing to Evinature’s pharmaceutical-grade cGMP manufacturing standards, custom assays, and tight quality control—including rejection of batches with active compounds that fall outside safe and effective ranges.
A New Standard in Nutraceutical Care
As Salomon concluded, “There are a lot of supplements out there. But the only way we feel comfortable addressing patient needs is by taking these through gold-standard science, just like we would any pharmaceutical.”
Blocker praised the transparency and dedication, noting that Evinature’s approach is “what’s needed to gain trust from both the medical community and patients alike.”
Check out the full interview below:
Evinature
